Genentech Sues Apotex Claiming Valcyte Patent Infringement
This article is for subscribers only.
Roche Holding AG’s Genentech unit sued Apotex Inc. for planning to sell a generic version of Valcyte, which treats a virus that afflicts transplant patients and people with AIDS, before Genentech’s patent for the drug expires.
Apotex, based in Toronto, told Genentech on April 6 that it had applied for approval from the U.S. Food and Drug Administration to make a generic of Valcyte, according to the complaint filed today in federal court in San Francisco.